Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease. A longevity startup has dosed its first patient with a drug to reverse age-related sight loss. Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year. It will be targeting patients with glaucoma and NAION, two conditions that cause damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain.